Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Recruiting · NCT07341867 · Registry updated 2026-08-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, skin disorder, triple-negative breast carcinoma, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-08-17 | NCT07341867 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Andrew Hantel, MD | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |